Question 1

How should we present success rates without falling foul of the HFEA?

Accepted Answer

By presenting them the way the regulator already publishes them, and resisting the temptation to find a flattering denominator. The HFEA collects outcome data from every licensed UK clinic and publishes it, which means a prospective patient can check your website against the regulator's own figures in about a minute — and the ones who are shortlisting five clinics will. Three things matter. First, the measure: a birth rate per embryo transferred and a birth rate per cycle started are very different numbers, and quoting only the more generous one without saying which it is invites exactly the challenge you do not want. Publish both, labelled. Second, age banding. Outcomes vary enormously with patient age, so a single clinic-wide figure is close to meaningless and reads as evasive to a woman of thirty-nine who knows perfectly well the average does not describe her. Break results down by band and state the time period and the number of cycles behind each figure, because a strong percentage drawn from a handful of cycles is not evidence. Third, selection. Reporting only a favourable subgroup, or comparing your best cohort against a national average calculated differently, is the classic breach. The commercial argument aligns with the compliance one here more cleanly than in most specialties: this patient has researched for months, has probably read the HFEA site already, and treats transparent reporting as the primary signal of whether a clinic can be trusted with the rest of it.

Question 2

Should we market treatment add-ons at all?

Accepted Answer

You can offer them, but market them against the published evidence rather than around it. The HFEA maintains a public rating system for fertility treatment add-ons, indicating how well the evidence supports each one for improving the chance of a live birth, and a number of widely sold add-ons carry ratings that make uncomfortable reading for anyone promoting them aggressively. Patients read that page. It is one of the most visited things the regulator publishes, and the fertility community discusses it constantly in forums and support groups. So a clinic promising an add-on will improve someone's chances, when the regulator has rated the evidence for exactly that as insufficient, creates a problem on two fronts: a regulatory one, and a credibility one the moment the patient cross-checks. The approach we take is to publish every add-on you offer with its current evidence rating shown plainly, alongside your own clinical reasoning for when you would and would not recommend it. Sometimes there is a legitimate case for a specific patient. Say so, and say what the evidence does and does not show. This looks commercially reckless until you watch how patients respond. In a market where many people feel add-ons are sold to them at their most vulnerable, the clinic that explains rather than upsells becomes the one recommended in support groups — and community recommendation moves more fertility patients in Britain than any advertising channel.

Question 3

How does the NHS funding lottery change our marketing?

Accepted Answer

It creates the demand and it tells you where to point it. NHS-funded fertility treatment in England is commissioned by integrated care boards, and what they fund varies substantially — the number of cycles offered, the upper age limit, BMI thresholds, criteria around existing children from a previous relationship, and rules for same-sex couples all differ by area. Scotland, Wales and Northern Ireland operate their own arrangements. The practical result is that two couples with identical circumstances a few miles apart can face completely different outcomes, and this is widely reported and widely resented. Every one of those disappointments is a self-pay patient being created, and almost all of them start by searching for what their own area funds. That search volume is enormous and most clinics have published nothing against it. Building genuinely useful, current pages explaining local funding criteria reaches people at the exact moment their expectation collapses, well before they have a clinic shortlist. The content has to be maintained, because criteria change and a stale page does real harm. Two further consequences follow. Your catchment is wider than you assume — patients denied funding will travel for treatment, and the monitoring schedule is manageable for a determined couple. And your cost pages carry more weight than in almost any other specialty, because this person was expecting to pay nothing and is now working out whether they can afford several thousand pounds without knowing if it will work.

Question 4

What does ivf & fertility marketing cost in the UK?

Accepted Answer

We quote clients in the UK in GBP. Google Business Profile management starts around GBP 50 per month and full-service retainers from about GBP 210 per month, scoped to how competitive your specialty and catchment are. IVF & Fertility is among the more contested categories in this market, so expect scope at the higher end where you are competing in a major city. Those figures are converted from our India list at an indicative rate and confirmed in writing after the free audit. Paid media sits outside our fee — in the UK treatment-intent clicks typically run £3–15.

Question 5

How quickly do ivf & fertility clinics see results in the UK?

Accepted Answer

Profile views, calls and direction requests usually move within 30 days, because the first wins come from fixing what is already indexed. Ranking and pipeline change typically lands between 60 and 90 days. IVF & Fertility has a longer consideration window than routine care — patients research, compare and often revisit over weeks — so the enquiry that arrives in month two frequently started in month one. We report against booked consultations rather than impressions for exactly that reason, and we sequence work so there is early traction on winnable searches while the contested head terms build.

IVF & Fertility marketing in the UK

Why this market behaves differently.

How they actually choose a clinic in the UK.

Funding discovery

National comparison

Evidence scrutiny

Open evening or consultation

The plays that work for this specialty in the UK.

Success rates presented the regulator's way

Whole-cost pages

Add-on honesty as a differentiator

Funding-criteria content by region

What the rules mean for ivf & fertility.